This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow [Supplementary Material]
Right arrow An erratum has been published
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scully, S. P.
Right arrow Articles by Gebhardt, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scully, S. P.
Right arrow Articles by Gebhardt, M. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?
The Journal of Bone and Joint Surgery (American) 84:49-57 (2002)
© 2002 The Journal of Bone and Joint Surgery, Inc.


Scientific Article

Pathologic Fracture in Osteosarcoma

Prognostic Importance and Treatment Implications

Sean P. Scully, MD, PhD, Michelle A. Ghert, MD, David Zurakowski, PhD, Roby C. Thompson, Jr.MD and Mark C. Gebhardt, MD in Representation of the Musculoskeletal Tumor Society

Investigation performed at the Musculoskeletal Oncology Division, Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina; Massachusetts General Hospital, Boston, Massachusetts; Oregon Health Sciences University, Portland, Oregon; Primary Children’s Hospital, Salt Lake City, Utah; University of California at Los Angeles, Los Angeles, California; University of Florida, Gainesville, Florida; University of Miami Medical Center, Miami, Florida; and University of Minnesota, Minneapolis, Minnesota

Sean P. Scully, MD, PhD
Department of Orthopaedic Surgery, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address: scully.sean{at}mayo.edu

Michelle A. Ghert, MD
Division of Orthopaedics, Department of Surgery, Duke University Medical Center, Durham, NC 27710

David Zurakowski, PhD
Departments of Orthopaedic Surgery and Biostatistics, Children’s Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115

Roby C. Thompson Jr., MD
Department of Orthopaedic Surgery, University of Minnesota Medical Center, 420 Delaware Street S.E., Minneapolis, MN 55455
Mark C. Gebhardt, MD
Department of Orthopaedic Surgery, Massachusetts General Hospital, 32 Fruit Street, Boston, MA 02114

The authors did not receive grants or outside funding in support of their research or preparation of this manuscript. They did not receive payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM (call our subscription department, at 781-449-9780, to order the CD-ROM).

Background: The presence of a pathologic fracture in an osteosarcoma has been considered a poor prognostic factor and an indication for immediate amputation. The purpose of the present study was to determine, in the current era of neoadjuvant chemotherapy, whether a pathologic fracture in an osteosarcoma has prognostic importance and whether limb salvage can be safely performed in such patients without compromising clinical outcome.

Methods: In a cooperative effort of the Musculoskeletal Tumor Society, members from eight institutions provided retrospective data on fifty-two patients with osteosarcoma who had a pathologic fracture and on fifty-five patients with osteosarcoma who had not had a pathologic fracture and had been followed for at least two years or until disease recurrence, metastasis, or death. The two groups were matched for patient age and tumor location. Outcomes examined were survival and local recurrence. A subgroup analysis was performed to assess differences in outcome within the group with the pathologic fracture.

Results: The five-year estimated survival rates were 55% for the group with a pathologic fracture and 77% for the group without a fracture (p = 0.02). The rate of survival without a local recurrence at five years was 75% for the group with a fracture and 96% for the group without a fracture (p = 0.007). In the group with a fracture, seven (23%) of the thirty patients managed with limb salvage and four (18%) of the twenty-two managed with an amputation had a local recurrence (p = 0.75). Eleven (37%) of the thirty patients with a fracture who were managed with limb salvage and ten (45%) of the twenty-two patients with a fracture who were managed with an amputation died of the disease (p = 0.50). Five patients underwent open reduction and internal fixation followed by limb-salvage surgery. Two of them had a local recurrence and died at an average of eight months postoperatively. The remaining three patients were alive at an average of 6.1 years postoperatively. Local disease control and the survival of these patients were not significantly different from those for the thirty-three patients who were treated with nonoperative immobilization of the fracture followed by limb-salvage surgery.

Conclusions: Patients with osteosarcoma who present with a pathologic fracture or sustain one during preoperative chemotherapy have an increased risk of local recurrence and a decreased rate of survival compared with patients who have not sustained a pathologic fracture. The performance of a limb-salvage procedure in carefully selected patients with a pathologic fracture does not significantly increase the risk of local recurrence or death. Factors predictive of improved outcome, such as the response to chemotherapy and union of the fracture, should be taken into account when limb salvage is being considered.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J Am Acad Orthop SurgHome page
P. J. Messerschmitt, R. M. Garcia, F. W. Abdul-Karim, E. M. Greenfield, and P. J. Getty
Osteosarcoma
J. Am. Acad. Ortho. Surg., August 1, 2009; 17(8): 515 - 527.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
F. Discepola, T. I. Powell, and A. Nahal
Best Cases from the AFIP: Telangiectatic Osteosarcoma: Radiologic and Pathologic Findings1
RadioGraphics, March 1, 2009; 29(2): 380 - 383.
[Full Text] [PDF]


Home page
JBJSHome page
M. S. Kocher and J. F. Sarwark
What's New in Pediatric Orthopaedics
J. Bone Joint Surg. Am., June 1, 2004; 86(6): 1337 - 1346.
[Full Text] [PDF]


Home page
JBJSHome page
M. S. Kocher and D. Zurakowski
Clinical Epidemiology and Biostatistics: A Primer for Orthopaedic Surgeons
J. Bone Joint Surg. Am., March 1, 2004; 86(3): 607 - 620.
[Full Text] [PDF]